Go to content


ViE Awards 2019 Nominees & Voting

Québec, an innovative city

Canadian Biotech Breaking New Ground in the Fight Against Infectious Disease

Life sciences - Québec International

Return of U.S. Flu Season Brings Worries About a Virulent Replay (Bloomberg)

Plant-Derived VLPs as a Novel Approach to Addressing an Unmet Need in Influenza Prevention

Medicago officially starts the construction of its site in Estimauville's Innovation Area

Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine

Medicago's Board of Directors asked company CEO Andy Sheldon to explore new business opportunities for Medicago.

This Company Is Testing a Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board (Forbes)

Medicago engaged by the canadian government to develop ebola monoclonal antibodies.

Medicago to build $245m production facility in Quebec city

Media Contact
Marie-Pier Côté
TACT Intelligence-conseil
| Media enquiries

Want to be the first to know about Medicago news?

Sign up for our newsletter.


Transforming the approach
to vaccines and therapeutic proteins

Here are the current published studies and contributions from Medicago's scientists and researchers.

October 31, 2018 Vaccine
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
Authors: So-Yoon Wona, Kristin Hunt, Hannah Guak, Benedeta Hasaj, Nathalie Charland, Nathalie Landry, Brian J. WardConnie M. Krawczyk
October 31, 2018
Investigation of an Adventitious Agent Test False Positive Signal in a Plant-Derived Influenza Vaccine
Authors: Todd L. Talarico, Michael Murphy, Raymond Nims, Dan Hastings, Jeri Ann Boose, and Dave Dumers
September 12, 2018
The adjuvant GLA-AF enhances human intradermal vaccine responses
Authors: Darrick Carter, Neal van Hoeven, Susan Baldwin, Yotam Levin, Efrat Kochba, Al Magill, Nathalie Charland, Nathalie Landry, Khin Nu, Aude Frevol, Jill Ashman, Zachary K. Sagawa, Anna Marie Beckmann, Steven G. Reed
April 24, 2018 Vaccine
Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada
Authors: David Champredon, Marek Laskowski, Nathalie Charland & Seyed M. Moghadas
February 23, 2018 Vaccine
Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
Authors: Lindsay BJ, Bonar MM, Costas-Cancelas IN, Hunt K, Makarkov AI, Chierzi S, Krawczyk CM, Landry N, Ward BJ, Rouiller I.
January 16, 2018 Human Vaccines & Immunotherapeutics
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
Authors: Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N.
October 11, 2017 Vaccine
A single intramuscular dose of a plant-made virus-like-particle vaccine elicits a balanced humoral and cellular response and protects young and aged mice from influenza H1N1 challenge 4despite a modest/absent humoral response
Authors: Breanna Hodgins, Karen K Yam, Kaitlin Winter, Stephane Pillet, Nathalie Landry and Brian J. Ward
July 2, 2017 Vaccine
Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.
Authors: Makarkov AI, Chierzi S, Pillet S, Murai KK, Landry N, Ward BJ
May 2, 2017 Human Vaccines & Immunotherapeutics
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Authors: Hendin HE, Pillet S, Lara AN, Wu CY, Charland N, Landry N, Ward BJ.
March 16, 2017 Vaccine
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro
Authors: Hilary E. Hendin, Stéphane Pillet, Amanda N. Lara, Cheng-Ying Wua, Nathalie Charland, Nathalie Landry, Brian J. Ward
July 24, 2016 Vaccine
Cell wall biochemical alterations during Agrobacterium-mediated expression of haemagglutinin-based influenza virus-like vaccine particles in tobacco
Authors: Franccois Le Mauff, Corinne Loutelier-Bourhis, Muriel Bardor, Caroline Berard, Alain Doucet, Marc-André D'Aoust, Louis-Philippe Vezina, Azeddine Driouich, Manon M.-J. Couture and Patrice Lerouge
October 2, 2015 Vaccine
Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets
Authors: S. Pillet, T. Racine, C. Nfond, T.Z. Di Lenardob, S. Babiukd, B.J. Ward, G.P. Kobingerc, N. Landry
June 2, 2015
Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP)
Authors: Katie R. Young, Guillaume Arthus-Cartier, Karen K. Yam, Pierre-Olivier Lavoie, Nathalie Landry, Marc-André D'Aoust, Louis-Philippe Vézina, Manon M.-J. Couture, and Brian J. Ward
April 21, 2015
Modulating secretory pathway pH by proton channel co-expression can increase recombinant protein stability in plants
Authors: Philippe V. Jutras, Marc-André D'Aoust, Manon M.-J. Couture, Louis-Philippe Vézina, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury
September 19, 2014
Human antibody response to N-glycans present on plant-madeinfluenza virus-like particle (VLP) vaccines
Authors: Brian J. Ward, Nathalie Landry, Sonia Trépanier, Geneviève Mercier,Michèle Dargis, Manon Couture, Marc-André D'Aoust, Louis-P. Vézinab
August 14, 2014
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens
Authors: Nathalie Landry, Stéphane Pillet, David Favre, Jean-François Poulin, Sonia Trépanier, Bader Yassine-Diab, Brian J. Ward
Events Stand Location

IDWeek 2018

834 October 3-7 | San Francisco, CA

Word Vaccine & Immunotherapy West Coast 2018

7 Nov 28-30 | San Diego, CA